OverviewSuggest Edit

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes supportive care products. The Company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The Company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes, and other product candidates, including other dronabinol line extensions and sublingual spray product candidates.

StateClosed
TypePublic
Founded1998
HQChandler, AZ, US
Websiteinsysrx.com
Employee Ratings2.1

Latest Updates

Employees (est.) (Dec 2018)226(-34%)
Revenue (FY, 2018)$82.1 M(-41%)
Share Price (Mar 2020)$0
Cybersecurity ratingAMore

Key People/Management at Insys Therapeutics

Saeed Motahari

Saeed Motahari

President and CEO
Andrew Long

Andrew Long

CFO
Franc Del Fosse

Franc Del Fosse

General Counsel
Sanga Emmanuel

Sanga Emmanuel

VP, Chief Compliance Officer
Venkat Goskonda

Venkat Goskonda

Senior VP, Research & Development
Daniel Pon

Daniel Pon

VP, Human Resources
Show more

Insys Therapeutics Office Locations

Insys Therapeutics has offices in Chandler and Round Rock
Chandler, AZ, US (HQ)
1333 S Spectrum Blvd #100
Chandler, AZ, US
444 S Ellis St
Round Rock, TX, US
2700 Oakmont Dr
Show all (3)

Insys Therapeutics Financials and Metrics

Insys Therapeutics Revenue

Embed Graph
View revenue for all periods
Insys Therapeutics's revenue was reported to be $82.08 m in FY, 2018
USD

Revenue (Q1, 2019)

7.6m

Gross profit (Q1, 2019)

3.1m

Gross profit margin (Q1, 2019), %

40%

Net income (Q1, 2019)

(123.8m)

EBIT (Q1, 2019)

(122.1m)

Market capitalization (25-Mar-2020)

3.1m

Closing stock price (25-Mar-2020)

0.0

Cash (31-Mar-2019)

36.5m

EV

(21.2m)
Insys Therapeutics's current market capitalization is $3.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

99.3m222.1m330.8m242.3m140.7m82.1m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7m22.6m28.9m25.4m20.6m10.8m

Gross profit

86.6m199.5m301.9m216.9m120.1m71.3m
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

11.1m18.8m29.2m41.6m55.7m58.3m70.8m77.6m91.3m62.0m67.1m55.2m36.0m42.6m30.7m23.9m23.5m18.3m7.6m

Cost of goods sold

1.8m2.6m3.1m4.8m6.6m5.4m6.4m8.3m7.7m4.6m6.3m4.7m4.6m3.9m7.5m2.2m3.6m2.4m4.6m

Gross profit

9.3m16.2m26.1m36.9m49.1m52.9m64.4m69.3m83.6m57.3m60.8m50.5m31.3m38.7m23.2m21.7m19.9m16.0m3.1m

Gross profit Margin, %

84%86%89%89%88%91%91%89%92%93%91%92%87%91%76%91%85%87%40%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

45.4m58.1m79.5m104.6m32.0m31.6m

Accounts Receivable

16.3m26.5m48.5m21.5m12.6m

Prepaid Expenses

1.7m2.2m4.0m19.8m9.4m

Inventories

14.5m34.8m41.7m21.7m17.4m8.6m
USDQ1, 2013

Debt/Equity

-0.2 x

Debt/Assets

0.5 x

Financial Leverage

-0.4 x
Show all financial metrics

Insys Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Insys Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Insys Therapeutics Online and Social Media Presence

Embed Graph

Insys Therapeutics News and Updates

Delisting of Securities of FTD Companies, Inc., Kaixin Auto Holdings (Warrant Only), CytRx Corporation, and Insys Therapeutics, Inc. from The Nasdaq Stock Market

NEW YORK, June 21, 2019 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of FTD Companies, Inc. FTD Companies, Inc.’s stock was suspended on June 13, 2019 and has not traded on Nasdaq since that time.  

Opioid drugmaker Insys Therapeutics files for bankruptcy

Drugmaker Insys Therapeutics Inc filed for Chapter 11 bankruptcy protection on Monday, about a week after agreeing to pay $225 million to settle a U.S. probe into bribes it paid to doctors for prescribing a powerful opioid medication.

Insys Therapeutics files for Chapter 11 bankruptcy

Drugmaker Insys Therapeutics Inc said on Monday it filed for Chapter 11 bankruptcy protection, a week after agreeing to pay $225 million to settle a U.S. probe into bribes the company paid to doctors for prescribing a powerful opioid medication. (Reporting by Manas Mishra in Bengaluru; Editing by An…

Insys Therapeutics founder, former executives found guilty in criminal fentanyl bribery case

A Boston jury convicted Insys Therapeutics founder John Kapoor and several other executives of racketeering and other crimes in a fentanyl bribery case that federal prosecutors say helped fuel the U.S. opioid epidemic.

Insys Therapeutics executives found guilty in opioid bribery scheme

A jury has found John Kapoor, the founder and former CEO of Insys Therapeutics, and 4 other executives guilty of a scheme that involved bribing doctors to prescribe the company's powerful opioid, Subsys, for patients who didn't need it and tricking health insurers to pay for it, Reuters reports.Why …

Global Medical Cannabis Market Growth Forecast Up to 2025 Analysis By Companies like BOL Pharma, Tilray, Medreleaf Corporation, Aurora Cannabis, Canopy Growth Corporation, Insys Therapeutics, Inc., Medical Marijuana Inc.

Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twitter @Indu…
Show more

Insys Therapeutics Blogs

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose Content Import Wed, 07/03/2019 - 06:01 FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment o…

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions Content Import Wed, 06/12/2019 - 08:01 INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions Jun 12, 2019 This release is a backfill from a News Wire G…

INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting

PHOENIX , March 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel

INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7

INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7 Content Import Wed, 03/06/2019 - 16:17 INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7 Mar 6, 2019 This release is a backfill from a News Wi…

INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology

Transformational momentum building as Company plans to apply for two NDAs in 2019 PHOENIX , Dec. 17, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today provided

INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy Content Import Tue, 12/04/2018 - 06:02 INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Ep…
Show more

Insys Therapeutics Frequently Asked Questions

  • When was Insys Therapeutics founded?

    Insys Therapeutics was founded in 1998.

  • Who are Insys Therapeutics key executives?

    Insys Therapeutics's key executives are Saeed Motahari, Andrew Long and Franc Del Fosse.

  • How many employees does Insys Therapeutics have?

    Insys Therapeutics has 226 employees.

  • What is Insys Therapeutics revenue?

    Latest Insys Therapeutics annual revenue is $82.1 m.

  • What is Insys Therapeutics revenue per employee?

    Latest Insys Therapeutics revenue per employee is $363.2 k.

  • Who are Insys Therapeutics competitors?

    Competitors of Insys Therapeutics include Assertio Therapeutics, ImmVira and ASLAN Pharmaceuticals.

  • Where is Insys Therapeutics headquarters?

    Insys Therapeutics headquarters is located at 1333 S Spectrum Blvd #100, Chandler.

  • Where are Insys Therapeutics offices?

    Insys Therapeutics has offices in Chandler and Round Rock.

  • How many offices does Insys Therapeutics have?

    Insys Therapeutics has 3 offices.